Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 6, 2008, Pages 345-350

  Koshiyama, Hiroyuki ^a,h   Taniguchi, Ataru ^b   Tanaka, Kiyoshi ^c   Kagimoto, Shinji ^d   Fujioka, Yoshio ^e   Hirata, Kenichi ^e   Nakamura, Yoshio ^f   Iwakura, Akane ^f   Hara, Kyoko ^f   Yamamoto, Taizo ^g   Kuroe, Akira ^b   Ohya, Michihiro ^b   Fujimoto, Shimpei ^b   Hamamoto, Yoshiyuki ^a,h   Honjo, Sachiko ^a   Ikeda, Hiroki ^a   Nabe, Koichiro ^a   Tsuda, Kinsuke ^h   Inagaki, Nobuya ^h   Seino, Yutaka ^b,h   Kume, Noriaki ^h   more..

^a Kitano Hospital   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c KYOTO WOMEN'S UNIVERSITY   (Japan)

^d Kamo Hospital   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^g KYOTO KATSURA HOSPITAL   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

Diabetes; HDL C; Inflammation; LDL C

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; AGED; CHEMISTRY; CLINICAL TRIAL; JAPAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

AGED; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; JAPAN; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; TRIGLYCERIDES;

EID: 59149099204     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E581     Document Type: Article

References (24)

1. Goldstein JL, Kita T, Brown MS: Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med, 1983; 309:288-296
2. Kume N, Kia T, Mikami A, Yokode M, Ishii K, Nagano Y, Kawai C: Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable, hyperlipidemic rabbits treated with CS-514 (pravastarin) and cholestyramine. Circulation, 1989; 79:1084-1090
3. Koshiyama H: The impact of statin treatment on diabetic, patients. Curr Opin Investig Drugs, 2003;4:395-400
4. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol, 2005; 16:624-629
5. Ridker PM, Rifai N, Pfeiffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998; 98:839-844
6. 22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci, 2000; 67:863-876
7. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakua T, Kodama T: The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb, 2002; 9:178-183
8. Kibayashi E, Urakaze M, Kobashi C, Kishida M, Takata M, Sato A, Yamazaki K, Kobayashi M: Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond), 2005; 108:515-521
9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002; 347:1557-1565
10. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 2001; 344:1959-1965
11. Taniguchi A, Nagasaka S, Fukushima M, Sasaki M, Okumura T, Yoshii S, Watanabe T, Ogura M, Yamadori N, Nin K, Kuroe A, Yamada Y, Seino Y, Nakai Y: C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients. Metabolism, 2002; 51:1578-1581
12. Albert MA, Danielson E, Rifai N, Ridker PM: PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a roundomized trial and cohort study. JAMA, 2001; 286:64-70
13. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001; 103:1933-1935
14. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton FS, Veves A: The effects of atorvastarin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab, 2004; 89:740-747
15. Hayashi T, Yokote K, Saito Y, Iguchi A: Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother, 2007; 8:2315-2327
16. Yoshitomi Y, Ishii T, Kaneki M, Tsujibayashi T, Sakurai S, Nagakura C, Miyauchi A: Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb, 2006; 13:108-113
17. Takemoto M, Kitahara M, Yokote K, Asaumi S, Take A, Saito Y, Mori S: NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol, 2001; 133:83-88
18. Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin W, Shim WJ, Ahn TH, HO Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS: Comparison of the efficicacy and tolerabiliry of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther, 2007; 29:2365-2373
19. Yamada S, Yanagawa T, Sasamoto K, Araki A, Miyao M, Yamanouchi T: Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism, 2006; 55:67-71
20. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364:685-696
21. Koshiyama H, Taniguchi A, Inagaki N, Seino Y: Is the concept of "cardiometabolic risk" more useful than "metabolic syndrome"? Diabet Med, 2007; 24:571
22. Liao JK: Safety and efficacy of statins in Asians. Am J Cardiol, 2007;99:410-414
23. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation, 2003; 107:1750-1756
24. Ridker PM, Cannon CP, Morrow D, Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastarin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI22) Investigators: C-reactive protein level and outcomes after statin therapy. N Engl J Med, 2005; 352:20-28